Apellis Pharmaceuticals (NASDAQ:APLS) Now Covered by Analysts at Cantor Fitzgerald

Cantor Fitzgerald assumed coverage on shares of Apellis Pharmaceuticals (NASDAQ:APLS) in a report published on Tuesday, Marketbeat reports. The firm issued an overweight rating and a $44.00 price target on the stock.

A number of other research firms have also recently weighed in on APLS. Royal Bank of Canada cut their price target on Apellis Pharmaceuticals from $24.00 to $21.00 and set a “sector perform” rating on the stock in a research note on Monday, April 21st. JPMorgan Chase & Co. raised their target price on Apellis Pharmaceuticals from $50.00 to $54.00 and gave the stock an “overweight” rating in a research report on Tuesday, March 4th. HC Wainwright reaffirmed a “buy” rating and issued a $57.00 price target on shares of Apellis Pharmaceuticals in a report on Monday, March 3rd. The Goldman Sachs Group cut their price objective on shares of Apellis Pharmaceuticals from $36.00 to $32.00 and set a “neutral” rating on the stock in a report on Monday, March 3rd. Finally, Scotiabank boosted their price objective on shares of Apellis Pharmaceuticals from $30.00 to $31.00 and gave the stock a “sector perform” rating in a research report on Wednesday, April 2nd. Eight investment analysts have rated the stock with a hold rating, eleven have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. According to data from MarketBeat, Apellis Pharmaceuticals currently has an average rating of “Moderate Buy” and an average price target of $45.28.

Apellis Pharmaceuticals Stock Up 1.4 %

NASDAQ:APLS opened at $18.21 on Tuesday. Apellis Pharmaceuticals has a 52 week low of $16.98 and a 52 week high of $49.06. The stock’s fifty day moving average is $22.49 and its two-hundred day moving average is $27.60. The company has a quick ratio of 3.73, a current ratio of 4.36 and a debt-to-equity ratio of 1.91. The stock has a market capitalization of $2.29 billion, a price-to-earnings ratio of -8.97 and a beta of 0.85.

Apellis Pharmaceuticals (NASDAQ:APLS) last posted its quarterly earnings data on Friday, February 28th. The company reported ($0.29) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.37) by $0.08. Apellis Pharmaceuticals had a negative return on equity of 103.11% and a negative net margin of 34.97%. The business had revenue of $212.50 million for the quarter, compared to analyst estimates of $197.92 million. During the same quarter in the prior year, the company earned ($0.73) earnings per share. The company’s revenue was up 45.2% on a year-over-year basis. Research analysts anticipate that Apellis Pharmaceuticals will post -1.7 EPS for the current year.

Insider Buying and Selling

In related news, General Counsel David O. Watson sold 5,569 shares of the firm’s stock in a transaction that occurred on Wednesday, March 5th. The stock was sold at an average price of $25.10, for a total value of $139,781.90. Following the completion of the transaction, the general counsel now directly owns 138,730 shares of the company’s stock, valued at $3,482,123. This trade represents a 3.86 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Over the last 90 days, insiders have sold 6,115 shares of company stock valued at $154,684. Corporate insiders own 6.80% of the company’s stock.

Institutional Trading of Apellis Pharmaceuticals

Several large investors have recently bought and sold shares of APLS. EverSource Wealth Advisors LLC boosted its position in shares of Apellis Pharmaceuticals by 2,707.1% in the 4th quarter. EverSource Wealth Advisors LLC now owns 786 shares of the company’s stock worth $25,000 after buying an additional 758 shares in the last quarter. Signaturefd LLC raised its position in Apellis Pharmaceuticals by 357.2% during the fourth quarter. Signaturefd LLC now owns 1,175 shares of the company’s stock worth $37,000 after acquiring an additional 918 shares during the last quarter. GF Fund Management CO. LTD. lifted its holdings in shares of Apellis Pharmaceuticals by 21.9% in the first quarter. GF Fund Management CO. LTD. now owns 3,185 shares of the company’s stock valued at $70,000 after purchasing an additional 573 shares in the last quarter. US Bancorp DE grew its position in shares of Apellis Pharmaceuticals by 70.0% in the fourth quarter. US Bancorp DE now owns 3,223 shares of the company’s stock valued at $103,000 after purchasing an additional 1,327 shares during the last quarter. Finally, Covestor Ltd grew its position in shares of Apellis Pharmaceuticals by 1,819.2% in the fourth quarter. Covestor Ltd now owns 3,992 shares of the company’s stock valued at $127,000 after purchasing an additional 3,784 shares during the last quarter. Institutional investors and hedge funds own 96.29% of the company’s stock.

About Apellis Pharmaceuticals

Apellis Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. It offers EMPAVELI for the treatment of paroxysmal nocturnal hemoglobinuria, C3 glomerulopathy and immune complex membranoproliferative glomerulonephritis, and hematopoietic stem cell transplantation-associated thrombotic microangiopathy; and SYFOVRE for treating geographic atrophy secondary to age-related macular degeneration and geographic atrophy (GA).